Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC By Ogkologos - July 14, 2026 126 0 Facebook Twitter Google+ Pinterest WhatsApp Findings after 7 years of follow-up in the CROWN study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Fructose Fuels Cancer Growth Indirectly, Lab Study Finds January 14, 2025 Pregnancy is Safe After Early Breast Cancer in Young Women with... July 17, 2020 2023 ASCO Annual Meeting Research Round Up: Progress in Preventing Melanoma... September 12, 2023 Our COVID-19 Response: How GreaterGood Is Making An Impact During The... April 23, 2020 Load more HOT NEWS Undetectable MRD and Extended PFS More Common with MRD-guided Ibrutinib-Venetoclax than... FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma How Are Eligibility Criteria for Clinical Trials Changing to Help People... New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer
